May 24, 2019
A False Claims Act case against former executives of newly bankrupt Aegerion Pharmaceuticals Inc. will likely survive a motion to dismiss, a Boston federal judge said Friday, suggesting the suit can move forward even though the government settled claims against the company and declined to intervene against the executives.
June 19, 2018
Former executives at Aegerion Pharmaceuticals Inc. argued Tuesday that a False Claims Act case against them ignores a federal regulatory program that gave marketers and doctors explicit permission to recommend an expensive cholesterol drug to people who did not have the rare genetic disorder it was created for.
March 16, 2018
A federal judge on Friday appointed a special master to keep a watchful eye on Aegerion Pharmaceuticals Inc. as it faces court-ordered audits and the payment of $36 million to patients who were unnecessarily prescribed its expensive cholesterol drug and to government health programs that footed the bill.
January 30, 2018
Patients harmed by a specialty cholesterol drug they were unnecessarily prescribed will get a slice of a $36 million forfeiture from Aegerion Pharmaceuticals Inc. instead of the government, a Massachusetts federal judge decided Tuesday in a criminal sentencing.